A study conducted at the Los Angeles Children ‘s Hospital is providing the best treatment for a rare invasive leukemia called mixed phenotype acute leukemia (MPAL).
Wannan binciken (ƙididdigar ƙididdiga na shekaru 20 na wallafe-wallafen kimiyya) ya gano cewa jiyya na MPAL tare da tsarin ƙananan ƙwayar cuta yana da alaƙa da fa'ida mai fa'ida ta gafara da yiwuwar rayuwa na dogon lokaci. An buga waɗannan binciken a cikin mujallar kan layi "Leukemia" a ranar 27 ga Fabrairu, 2018.
MPAL accounts for 2% -5% of leukemia cases, which is historically difficult to treat, and the 5-year survival rate is less than 50%. The disease affects children and adults and is characterized by two common forms of leukemia: acute lymphocytic leukemia (ALL) and m myeloid leukemia (AML).
Dole ne likitan ya yanke shawarar ko zai yi amfani da ALL ko AML, ko cakuda hanyoyin biyu. Babu cikakkiyar yarjejeniya akan wace hanya ce mafi kyau. Saboda wannan cutar ba ta da yawa, dubban marasa lafiya ba a gwada su a asibiti don sanin tsarin kulawa mafi kyau ba. Maimakon haka, an buga rahotanni ƙanana, keɓantacce, sau da yawa kuma masu karo da juna a cikin mujallun da ake yaɗawa a duniya.
Don ƙarin fahimtar binciken da ake da shi da kuma samar wa likitoci ƙarin jagorar jiyya, Orgel da ƙungiyar bincike na CHLA sun gudanar da bita na farko na lura da tsarin bincike na MPAL. A ƙarshe ƙungiyar ta taƙaita jerin zuwa takardu 252 masu alaƙa daga ƙasashe 33, waɗanda suka haɗa da marasa lafiya 1,499. Mahimman binciken su: Marasa lafiya da aka fara bi da su tare da DUKAN (masu lafiya da ƙananan ƙwayar cuta) sun kasance 3 zuwa 5 sau mafi kusantar samun cikakkiyar gafara fiye da marasa lafiya da aka bi da su tare da AML. Marasa lafiya waɗanda suka karɓi maganin gaurayawa sun yi mafi muni.
Binciken ya nuna mahimmancin buƙatar gwaji na asibiti don ƙayyade mafi kyawun magani ga MPAL kuma yana taimakawa wajen inganta maganin wannan cuta mai wuyar gaske.
